ABSTRACT
tibiotics has increased the appearance of multidrug resistant P. aeruginosa (MDRPA) isolates which complicates the process of therapy and limits treatment options (4) .
Multidrug resistant is defined as being resistant to at least 3 anti-pseudomonal antibiotic-groups including β-lactams, aminoglycosides, and fluoroquinolones (5) . Carbapenems are antibiotics used for treatment of hospitalized patients infected with MDRPA (6) . These antibiotics are a class of β-Lactam antibiotics with a broad spectrum of antibacterial activity and have the broadest antibacterial spectrum compared to other β-lactams such as penicillins and cephalosporins (7) . However, the incidence 
INTRODUCTION
Pseudomonas aeruginosa is one of the most prevalent opportunistic human pathogen causing several clinical infections including wound infection, pneumonia, urinary tract infections, endocarditis, meningitis, brain abscess, and bacteremia (1) (2) (3) . The increasing inappropriate use of broad-spectrum an-of carbapenem resistance among clinical isolates of P. aeruginosa has been raised, predominantly due to production of carbapenemases, including the imipenem metallo-β-lactamase (IMP), VIM (Verona imipenemase), SPM (São Paolo metallo-β-lactamase), and GIM (German imipenemase) (3, 8) .
MBLs were first formally categorized from serine β-lactamases in 1980 in molecular classification scheme proposed by Ambler (9) . In 1989, Bush further classified MBLs into a separate group (group 3) according to their functional properties (10) . The MBLs-mediated resistance is important emerging resistance mechanisms in P. aeruginosa and is therefore associated with significant morbidity and mortality (3, 11) . MBL activity is inhibited by metal chelators, such as EDTA and THIOL compounds. These enzymes can hydrolyze most beta-lactam antibiotics including, penicillins, cephalosporins and carbapenems except monobactams (12, 13) .
The bla IMP , bla VIM , bla SPM and bla NDM-1 -encoding genes responsible for MBL production are horizontally transferable via plasmids and can rapidly spread to other bacteria (6) . The first reported of mobile MBLs was with the discovery of P. aeruginosa strain GN17203 from Japan in 1988 (14) . The IMP enzymes were originally detected in Asia, but later spread to Europe, to the United States and to Australia, while the VIM gene was first found in Europe, and shortly after emerged to other countries (3) . The aims of this study were (i) to access the antimicrobial susceptibility of P. aeruginosa isolated from educational hospitals of Qazvin and Alborz provinces, (ii) to determine the prevalence of MBLs among carbapenem non-susceptible isolates by CD test, (iii) and to detect the bla IMP , bla VIM , bla SIM , bla GIM , bla SPM and bla NDM-1 genes in MBL-producing isolates.
MATERIALS AND METHODS

Study design and identification.
A total of 300 non-repetitive P. aeruginosa isolates were obtained from the different clinical specimens of patients admitted in Qazvin and Alborz educational hospitals. The bacterial isolates were collected from January of 2011 until November 2013. These isolates were identified by standard laboratory methods including bacteriologic and biochemical methods such as; Gram staining, oxidase test, growth at 42°C, growth on cetrimide agar medium (Liofilchem, Italy), O/F (Oxidation-Fermentation) test and pigment production (15) . The isolates were collected from various clinical specimens including tracheal aspirate, urine, sputum, blood, wound, and bronco alveolar lavage. These isolates were stored at -70°C in trypticase soy broth containing 20% glycerol and sub cultured twice prior to testing.
Antimicrobial susceptibility testing. This test was performed using Kirby-Bauer disc diffusion method according to the CLSI guideline (16) . The following antibiotic discs were used: cefepime (30 µg), amikacin (30 µg), aztreonam (30 µg), polymyxin B (10 µg), imipenem (10 µg), meropenem (10 µg), gentamicin (10 µg), piperacillin/tazobactam (100/10µg), piperacillin (100 µg), ceftazidim (30 µg), cefotaxime (10 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), ofloxacin (10 µg), ticarcillin (10 µg), carbenicillin (10 µg) and tobramycin (10 µg). Antibiotic discs were purchased from Mast (Mast Diagnostics Group Ltd, Merseyside, UK). P. aeruginosa ATCC 27853 was used as the quality control strain in antimicrobial susceptibility testing. MBL screening and confirmation by phenotypic methods. Kirby-Bauer disk diffusion test was performed in order to screen MBL production using imipenem (10µg) and meropenem (10 µg) disks. Isolates that were non-susceptible to carbapenem antibiotics in combined disc method, were used as a potential MBL producer. In brief a 0.5 M EDTA solution was prepared and then was added to 10 µg imipenem disks to obtain a concentration of 750 µg. The bacterial suspension equivalent to 0.5 McFarland turbidity was prepared and was inoculated onto plates of Mueller-Hinton agar as recommended by the CLSI. The imipenem and imipenem-EDTA disks were placed on the plate. The inhibition zones of these disks with and without EDTA solution were compared after 16-18 hours of incubation in air at 35ºC. An increase of ≥7 in the zone diameter for imipenem in the presence of EDTA was considered as positive result (13) .
Detection of MBL-encoding genes by PCR
and sequencing. All MBL-producing isolates were subjected to PCR for detection of bla IMP-1 , bla IMP-2 , bla VIM-1 , bla VIM-2 , bla SPM , bla SIM , bla GIM and bla NDM-1 genes, using specific primers (Table 1) (17) (18) (19) .
Total DNAs were extracted by the DNA extraction kit (Bioneer Company-Korea). PCR amplifications were performed in a thermocycler (Applied Biosystems, USA) as follows: 95ºC for 5min and 35 cycles of 1min at 95ºC, 1min at specific annealing temperature for each primer and 1min at 72ºC. A final extension step of 10 min at 72ºC was performed. Amplification reactions were prepared in a total volume of 25μl (24μl of PCR master mix plus 1μl of template DNA) including 5ng of genomic DNA, 2.0U of Taq DNA polymerase, 10mM dNTP mix at a final concentration of 0.2mM, 50mM MgCl 2 at a final concentration of 1.5mM, 1μM of each primer, and 1X PCR buffer (final concentration). PCR products were electrophoresed on 1% agarose gel and then were stained with ethidium bromide solution and finally visualized using gel documentation system (UVtec, UK). The purified PCR products were sequenced by the Macrogen Company (Seoul, South Korea) and the sequence alignment and analysis were performed online using the BLAST program of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
Statistical analysis. Statistical data analysis was performed for descriptive statistics, including frequencies, cross tabulation of microbiological, clinical features and demographic characteristics us- Table 1 . Oligonucleotide primers used in this study TTGGGGATG TGAGACTAC  TCGACACACCTTGGTCTG  AACTTCCAACTTTGCCAT  TACAAGGGATTCGGCATCC  TAATGGCCTGTTCCCATG  GGCGGAATGGCTCATCACGA  CGCAACACAGCCTGACTTTC   17   17   17   17   17   18   18   19 ing the computer software program SPSS version 16.
RESULTS
In this study, 96 (32 %) isolates were collected from the patients admitted to intensive care unit (ICU), 100 (33.3 %) infection diseases, 61 (20.3 %) internal medicine, 30 (10 %) surgery, 8 (2.7 %) neurosurgery and 5 (1.7 %) neurology wards. Our bacterial isolates were recovered from blood (108-36%), urine (91-30.33%), wound (34-11.33%), bronco alveolar lavage (23-7.66 %), trachea secretions (23-7.66%) and sputum (21-7%) samples. One hundred fifty-six patients (52%) were female and 144 (48%) were male. The mean age of the patients was 51.07±18.8 (range 18-90) years.
Antimicrobial susceptibility. The high rates of antibiotic resistance were against cefotaxime (92.7 %) and aztreonam (57.7%). Polymyxin B, amikacin and piperacillin/tazobactam revealed high susceptibility rates of 98.3%, 71.3% and 64.7 %, respectively. One hundred one (33.7%) isolates were characterized as MDRPA i.e., were intermediate or resistance to at least three different classes of antimicrobial agents including β-lactams, aminoglycosides and fluoroquinolones. In total, 107 (35.66%) isolates were Reference non-susceptible to imipenem and/or meropenem ( Table 2) .
Detection of MBL by CD and PCR methods.
Among 107 carbapenem non-susceptible P. aeruginosa isolates, 56 (52.3%) isolates were MBL producer. PCR and sequencing showed that 24 (42.85%) isolates were positive for MBL genotypes among those 14 (25%) isolates and 10 (17.85%) isolates carried bla IMP-1 and bla VIM-1 genes either alone or in combination. Three (5.35%) isolates carried both the bla IMP-1 and bla VIM-1 genes, simultaneously. Isolates were negative for bla IMP-2 , bla VIM-2 , bla GIM , bla SIM , bla NDM-1 and bla SPM genes (Table3). 
DISCUSSION
Despite the rapid development of antibiotics and improvement in supportive care, P. aeruginosa remains one of the most serious health care associated infections with high rate of mortality and morbidity. This (20) . Carbapenems (imipenem and meropenem) are the most active agents for treating of nosocomial infections caused by P. aeruginosa isolates (3). However, the emergence of carbapenem resistant P. aeruginosa isolates has be-come a serious clinical concern because of its intrinsic and acquired resistance mechanisms, limiting the treatment options (21) . MBLs are increasingly widespread around worldwide as important mechanisms of carbapenem resistance among P. aeruginosa (3, 6, 22) .
In the present study, antimicrobial susceptibility results showed that 33.7% isolates were MDRPA with significant rate of resistance against common used antibiotics. These findings are in agreement with results of previous studies in Iran, which reported that P. aeruginosa isolates are resistant to many classes of antibiotics (23, 24) .
Overall, resistance to imipenem and/or meropenem was 35.66% which is higher than results of other studies have been reported by Shahcheraghi et (30) , indicating the MBL-producing P. aeruginosa is increasing. It should be noted that 48.7% of carbapenem resistant P. aeruginosa were MBL negative which suggest other mechanisms might alternatively be contributed in the carbapenem resistance, most importantly production of oxacilinase or deficiency in porin or reduced expression of outer membrane proteins (3). We previously reported that 31 (49%) of A. baumannii isolates were found to be MBL producers (31) .
In the present study, of 56 MBL-producing isolates, 24 (42.85%) isolates were positive for MBL genotypes which 14 (25%) isolates and 10 (17.85%) isolates carried bla IMP-1 and bla VIM-1 genes either alone or in combination. In recent years, bla IMP and bla VIM -producing P. aeruginosa isolates have been reported in Asian countries. In a study from Iran, Sarhangi et al. reported that 8 (9.75%) and 10 (12.19%) of MBL-producing P. aeruginosa isolates were positive for bla IMP-1 and bla VIM-1 genes, respectively (32 (30) . This study showed that most bla IMP-1 and bla VIM-1 -positive P. aeruginosa isolates were frequently collected from the patients admitted to intensive care and infection disease units. It seems that chronic underlying conditions, prolonged period of ICU stay and the use of invasive techniques and devices predispose patients to infection with these resistant isolates.
In conclusion, results of this study revealed the considerable prevalence of MBL-producing P. aeruginosa isolates in our hospital settings. Moreover, the MBL-encoding genes often carried by mobile genetic elements which can rapidly spread horizontally between different strains. However, early recognition of MBL-producing isolates and establishing tactful policies associated with infection control measures and appropriate antimicrobial therapy based on laboratory data are necessary to reduce further spread of these resistant bacteria in our hospitals.
ACKNOWLEDGMENT
This study was financially supported by the Cellular and Molecular Research Center and Research Deputy of Qazvin University of Medical Sciences, Qazvin, Iran.
